Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
2022 · Nature Communications · 96 citations
https://doi.org/10.1038/s41467-022-30569-0
Z
Zhenluan Tian
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
20
Papers
461
Citations
6
h-index
5
i10-index
Zhenluan Tian is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Venous Thromboembolism Diagnosis and Management & Cancer-related molecular mechanisms research. The author has an h-index of 6, co-authored 17 publications.
Papers by this author
worksPrognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer
2020 · Breast Cancer · 12 citations
https://doi.org/10.1007/s12282-020-01142-8
Unsupervised and supervised machine learning to identify variability of tumor-educated platelets and association with pan-cancer: A cross-national study
2023 · Fundamental Research · 1 citations
https://doi.org/10.1016/j.fmre.2023.09.004
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat